Development of newborn screening policies in Spain 2003-2022: what do we actually need to reach an agreement?

Abstract

Newborn screening (NBS) for inherited disorders is recognized as an essential public health intervention to improve health outcomes in the newborn population. The implementation of an NBS programme requires an evaluation of effectiveness, safety, cost-effectiveness, feasibility, and budget impact. Determining which of the known disorders should be included in NBS programmes is a public health policy challenge. In this context, economic evaluation aims to contribute to the sustainability of public health systems, but the appropriate economic evaluation framework for these interventions is still unclear. Existing NBS programmes vary widely in the number and type of disorders screened, even among the most developed European countries, despite the fact that the core criteria for guiding policy decision-making are standard. In Spain, where delivery of NBS programmes is marked by heterogeneity between regions, guidelines based on the best available scientific evidence are being established in order to achieve standardization of NBS policies and programmes at a national level. This paper provides a general overview of existing evidence-based health-policy initiatives aimed at enhancing the equity and efficiency of the NBS programme in Spain and their impact on health decisions. We also describe existing challenges to reduce uncertainty, and the variations observed in decisions relating to the content and procedures used in NBS programmes.

Keywords

Newborn screening / inherited disorders / health-policy / equity

References

[1] Bailey DB Jr.A window of opportunity for newborn screening.Mol Diagn Ther2022;26:253-61 PMCID:PMC9098569

[2] Bailey DB Jr,Lewis MA.Early check: translational science at the intersection of public health and newborn screening.BMC Pediatr2019;19:238. PMCID:PMC6636013

[3] Loeber JG,Cornel MC.Newborn screening programmes in Europe; arguments and efforts regarding harmonization. Part 1. From blood spot to screening result.J Inherit Metab Dis2012;35:603-11

[4] Chan K,Williams MS.Population-based screening of newborns: Findings from the newborn screening expansion study (part two).Front Genet2022;13:867354. PMCID:PMC9476322

[5] Kemper AR,Calonge N.Decision-making process for conditions nominated to the recommended uniform screening panel: statement of the US Department of Health and Human Services Secretary’s Advisory Committee on heritable disorders in newborns and children.Genet Med2014;16:183-7.

[6] Brower A,Williams M.Population-based screening of newborns: findings from the NBS expansion study (part one).Front Genet2022;13:867337. PMCID:PMC9354846

[7] Lyon J.Concerns over newborn screening.JAMA2017;317:576

[8] Jones SA,Chakrapani A.Application of a novel algorithm for expanding newborn screening for inherited metabolic disorders across Europe.Int J Neonatal Screen2022;8:20 PMCID:PMC8951961

[9] Loeber JG,Zetterström RH.Neonatal screening in Europe revisited: an ISNS perspective on the current state and developments since 2010.Int J Neonatal Screen2021;7:15

[10] Scarpa M,Dionisi-Vici C.Newborn screening as a fully integrated system to stimulate equity in neonatal screening in Europe.Lancet Reg Health Eur2022;13:100311 PMCID:PMC8841274

[11] Wilson JMG. World Health Organization principles and practice of screening for disease. Geneva; 1968. Available from: https://niercheck.nl/wp-content/uploads/2019/06/Wilson-Jungner-1968.pdf [Last accessed on 13 Sep 2023]

[12] Andermann A,Beauchamp S.Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years.Bull World Health Organ2008;86:317-9 PMCID:PMC2647421

[13] Jansen ME,Lister KJ.International differences in the evaluation of conditions for newborn bloodspot screening: a review of scientific literature and policy documents.Eur J Hum Genet2016;25:10-6 PMCID:PMC5159762

[14] Sikonja J,Scarpa M.Towards achieving equity and innovation in newborn screening across Europe.Int J Neonatal Screen2022;8:31 PMCID:PMC9149820

[15] Botkin JR,Fost NC.Newborn screening technology: proceed with caution.Pediatrics2006;117:1793-9

[16] Friedman JM,Goldenberg AJ,Sénécal K.Global Alliance for Genomics and Health Regulatory and Ethics Working Group Paediatric Task TeamGenomic newborn screening: public health policy considerations and recommendations.BMC Med Genomics2017;10:9 PMCID:PMC5320805

[17] Howard HC,Cornel MC,Sénécal K.European Society of Human GeneticsP3G International Paediatric PlatformHuman Genome Organisation; and the PHG FoundationWhole-genome sequencing in newborn screening? A statement on the continued importance of targeted approaches in newborn screening programmes.Eur J Hum Genet2015;23:1593-600 PMCID:PMC4795188

[18] Johnston J,Goldenberg A,Parens E.members of the NSIGHT Ethics and Policy Advisory BoardSequencing newborns: a call for nuanced use of genomic technologies.Hastings Cent Rep2018;48 Suppl 2:S2-6 PMCID:PMC6901349

[19] Knoppers BM,Borry P.Whole-genome sequencing in newborn screening programs.Sci Transl Med2014;6:229cm2

[20] Potter BK,Entwistle V.Ethical, legal, and social issues in health technology assessment for prenatal/preconceptional and newborn screening: a workshop report.Public Health Genomics2009;12:4-10 PMCID:PMC2790790

[21] Castilla I,Valcárcel-Nazco C. Cost-effectiveness of the expanded newborn screening of congenital errors of metabolism using tandem mass spectrometry. Available from: https://sescs.es/coste-efectividad-cribado-de-errores-congenitos-del-metabolismo-mediante-espectrometria-de-masas/ [Last accessed on 13 Sep 2023]

[22] Ramos-Goñi JM,Espada Sáenz-Torres M. Coste-efectividad del cribado neonatal de los errores congénitos del metabolismo mediante espectrometría de masas en tándem. Madrid; 2008. Report No.: Servicio de Evaluación del Servicio Canario de la Salud. SESCS; 2006. Available from: https://sescs.es/coste-efectividad-del-cribado-neonatal-por-espectrometria-de-masas-en-tandem/ [Last accessed on 13 Sep 2023]

[23] Castiñeras DE,Marin JL,Rocha H.Newborn screening for metabolic disorders in Spain and worldwide.An Pediatr2019;91:128.e1-14

[24] Chan K.Simple test, complex system: multifaceted views of newborn screening science, technology, and policy.Glob Pediatr Health2019;6:2333794X19894812 PMCID:PMC6926981

[25] Hoffmann GF,Loeber JG.50 years of newborn screening.J Inherit Metab Dis2014;37:163-4

[26] Serrano-aguilar P,Vallejo-torres L,García-pérez L.Neonatal screening in Spain and cost-effectiveness.Expert Opinion on Orphan Drugs2015;3:971-4

[27] Cacciatore P,Buyukkaramikli N,van den Akker-van Marle ME.The methodological quality and challenges in conducting economic evaluations of newborn screening: a scoping review.Int J Neonatal Screen2020;6:94 PMCID:PMC7712813

[28] Garavito GA, Moniz T, Déom N, Redin F, Pichini A, Vindrola-Padros C. The implementation of large-scale genomic screening or diagnostic programmes: A rapid evidence review.Eur J Hum Genet2023;31:282-95 PMCID:PMC9995480

[29] Pollitt RJ,Mccabe CJ.Neonatal screening for inborn errors of metabolism: cost, yield and outcome: a review.Health Technol Asses1997;1

[30] Baily MA.Ethics, evidence, and cost in newborn screening.Hastings Cent Rep2008;38:23-31

[31] Chan K,Pai SY,Puck JM.A markov model to analyze cost-effectiveness of screening for severe combined immunodeficiency (SCID).Mol Genet Metab2011;104:383-9 PMCID:PMC3205197

[32] Gaspar HB,Mahlaoui N,Borte S.The case for mandatory newborn screening for severe combined immunodeficiency (SCID).J Clin Immunol2014;34:393-7

[33] Johnson K,Mann MY,Therrell BL.Financing state newborn screening programs: sources and uses of funds.Pediatrics2006;117:S270-9.

[34] Howell RR.Ethical issues surrounding newborn screening.Int J Neonatal Screen2021;7:3 PMCID:PMC7838989

[35] Simon D,Baker M.Common challenges and identified solutions for state newborn screening programs during COVID-19 pandemic.Int J Neonatal Screen2022;8:7 PMCID:PMC8883950

[36] Ley 14/1986, de 25 de abril, General de Sanidad. Available from: https://www.boe.es/eli/es/l/1986/04/25/14/con [Last accessed on 9 Sep 2023]

[37] Royal Decree 1030/2006, of September 15, which establishes the portfolio of common services of the National Health System and the procedure for updating it. Available from: https://www.boe.es/eli/es/rd/2006/09/15/1030/con [Last accessed on 13 Sep 2023]

[38] Couce ML,Bóveda MD.Evaluation and long-term follow-up of infants with inborn errors of metabolism identified in an expanded screening programme.Mol Genet Metab2011;104:470-5

[39] The Spanish Network of Agencies for Health Technology Assessment and Services of the National Health System (RedETS); 2023. Available from: https://redets.sanidad.gob.es/ [Last accessed on 9 Sep 2023]

[40] Royal Decree-Law 16/2012, of April 20, on urgent measures to guarantee the sustainability of the National Health System and improve the quality and safety of its benefits; 2012. Available from: https://www.boe.es/eli/es/rdl/2012/04/20/16/con [Last accessed on 9 Sep 2023]

[41] Sobrido Prieto M, González Guitián C, Cerdá Mota T, group of technicians and experts in documentation, and diffusion/dissemination belonging to the Spanish Health Technology Assessment Agencies & Units. Strategies for the diffusion and dissemination of health technology assessment (HTA) products. Madrid: Ministry of Science & Innovation; 2010. Available from: https://redets.sanidad.gob.es/productos/buscarProductos.do?metodo=descargarFichero&idProducto=135 [Last accessed on 9 Sep 2023]

[42] Langer A,John J.Specific guidelines for assessing and improving the methodological quality of economic evaluations of newborn screening.BMC Health Serv Res2012;12:300 PMCID:PMC3459803

[43] Vallejo-Torres L,Serrano-Aguilar P.Estimating a cost-effectiveness threshold for the Spanish NHS.Health Econ2018;27:746-61.

[44] Valcárcel-Nazco C,Linertová R. Cost-effectiveness methods of newborn screening assessment. Rev Esp Salud Publica 2021;95:e202101009. Available from: https://www.mscbs.gob.es/biblioPublic/publicaciones/recursos_propios/resp/revista_cdrom/VOL95/C_ESPECIALES/RS95C_202101009.pdf [Last accessed on 9 Sep 2023]

[45] Grosse SD,Ding Y.The use of economic evaluation to inform newborn screening policy decisions: the washington state experience.Milbank Q2016;94:366-91 PMCID:PMC4911729

[46] Forman J,Levy-Fisch J,Terry S.Screening criteria: the need to deal with new developments and ethical issues in newborn metabolic screening.J Community Genet2013;4:59-67 PMCID:PMC3537969

[47] Nicholls SG.Informed choice for newborn blood spot screening in the United Kingdom: a survey of parental perceptions.Pediatrics2012;130:e1527-33

[48] Wright SJ,Dharni N.Eliciting preferences for information provision in newborn bloodspot screening programs.Value Health2017;20:651-61

[49] Bailey DB Jr.Newborn screening: evolving challenges in an era of rapid discovery.JAMA2015;313:1511-2 PMCID:PMC7990125

[50] Wasserstein MP,Arnold G.Clinical outcomes of children with abnormal newborn screening results for Krabbe disease in New York State.Genet Med2016;18:1235-43

[51] Howson CP,Giugliani R.Universal newborn screening: a roadmap for action.Mol Genet Metab2018;124:177-83.

[52] Pollitt RJ.International perspectives on newborn screening.J Inherit Metab Dis2006;29:390-6

[53] Fischer KE,Rogowski WH.The role of health technology assessment in coverage decisions on newborn screening.Int J Technol Assess Health Care2011;27:313-21

[54] Fischer KE.Funding decisions for newborn screening: a comparative review of 22 decision processes in Europe.Int J Environ Res Public Health2014;11:5403-30 PMCID:PMC4053875

[55] Cameron D,Norström F.On what basis are medical cost-effectiveness thresholds set? Clashing opinions and an absence of data: a systematic review.Glob Health Action2018;11:1447828 PMCID:PMC5930346

[56] Eichler HG,Gerth WC,Jönsson B.Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?.Value Health2004;7:518-28

[57] Marsh KD,Caro JJ.The use of MCDA in HTA: great potential, but more effort needed.Value Health2018;21:394-7

[58] Boy N,Thimm E.Newborn screening: a disease-changing intervention for glutaric aciduria type 1.Ann Neurol2018;83:970-9.

[59] Gramer G,Feyh P.Newborn screening for vitamin B12 deficiency in Germany-strategies, results, and public health implications.J Pediatr2020;216:165-72.e4

[60] Mütze U,Gramer G.Long-term outcomes of individuals with metabolic diseases identified through newborn screening.Pediatrics2020;146:e20200444

[61] Hall K.12th ISNS European regional meeting oral and poster abstracts.Int J Neonatal Screen2021;7:71 PMCID:PMC8628898

[62] Garrison LP Jr,Erickson P,Mullins CD.Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report.Value Health2007;10:326-35